GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cogstate Ltd (ASX:CGS) » Definitions » ROE % Adjusted to Book Value

Cogstate (ASX:CGS) ROE % Adjusted to Book Value : 2.43% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Cogstate ROE % Adjusted to Book Value?

Cogstate's ROE % for the quarter that ended in Dec. 2023 was 10.62%. Cogstate's PB Ratio for the quarter that ended in Dec. 2023 was 4.37. Cogstate's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was 2.43%.


Cogstate ROE % Adjusted to Book Value Historical Data

The historical data trend for Cogstate's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cogstate ROE % Adjusted to Book Value Chart

Cogstate Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.18 -3.85 3.24 5.03 2.03

Cogstate Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.16 4.02 0.05 3.86 2.43

Competitive Comparison of Cogstate's ROE % Adjusted to Book Value

For the Health Information Services subindustry, Cogstate's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cogstate's ROE % Adjusted to Book Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cogstate's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Cogstate's ROE % Adjusted to Book Value falls into.



Cogstate ROE % Adjusted to Book Value Calculation

Cogstate's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=10.32% / 5.09
=2.03%

Cogstate's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=10.62% / 4.37
=2.43%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cogstate ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Cogstate's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Cogstate (ASX:CGS) Business Description

Traded in Other Exchanges
Address
161 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cogstate Ltd is a cognitive science company. The principal activity of the company is the sale of technology and services for the measurement of cognition, where services include scientific consultancy, project management, data management, statistical analysis, and reporting. Its operating segment includes Clinical Trials; Healthcare and Research. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.

Cogstate (ASX:CGS) Headlines

No Headlines